Immunome (NASDAQ:IMNM) Insider Sells $1,244,100.00 in Stock

Immunome, Inc. (NASDAQ:IMNM) insider Robert Lechleider sold 55,000 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $22.62, for a total value of $1,244,100.00. Following the transaction, the insider owned 15,805 shares in the company, valued at approximately $357,509.10. This trade represents a 77.68% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Robert Lechleider also recently made the following trade(s):

• On Thursday, June 25th, Robert Lechleider sold 55,000 shares of Immunome stock. The shares were sold at an average price of $19.85, for a total value of $1,091,750.00.

Immunome Price Performance

Shares of NASDAQ:IMNM opened at $24.16 on Friday. The company has a market capitalization of $2.74 billion, a price-to-earnings ratio of -10.15 and a beta of 2.07. The firm’s 50 day simple moving average is $21.01 and its 200 day simple moving average is $21.87. Immunome, Inc. has a fifty-two week low of $7.96 and a fifty-two week high of $27.65.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.12. Equities research analysts expect that Immunome, Inc. will post -2.06 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on IMNM shares. Barclays initiated coverage on shares of Immunome in a report on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price target for the company. HC Wainwright reiterated a “buy” rating on shares of Immunome in a report on Thursday. Leerink Partners lowered their price target on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a report on Friday, May 15th. Wedbush reaffirmed an “outperform” rating and set a $31.00 price target on shares of Immunome in a research report on Friday, June 12th. Finally, Truist Financial lifted their price objective on Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, May 28th. Thirteen equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Immunome has an average rating of “Moderate Buy” and an average price target of $33.17.

Institutional Investors Weigh In On Immunome

A number of hedge funds and other institutional investors have recently made changes to their positions in IMNM. T. Rowe Price Investment Management Inc. boosted its stake in Immunome by 59.4% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 13,421,987 shares of the company’s stock worth $288,305,000 after purchasing an additional 5,003,824 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Immunome by 8,659.2% in the 4th quarter. JPMorgan Chase & Co. now owns 2,855,747 shares of the company’s stock valued at $61,341,000 after purchasing an additional 2,823,144 shares during the period. Primecap Management Co. CA raised its stake in shares of Immunome by 55.2% in the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after purchasing an additional 1,667,432 shares during the period. Balyasny Asset Management L.P. bought a new stake in shares of Immunome in the fourth quarter valued at about $30,710,000. Finally, Sofinnova Investments Inc. lifted its holdings in shares of Immunome by 271.2% in the fourth quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock valued at $34,765,000 after purchasing an additional 1,182,426 shares in the last quarter. 44.58% of the stock is currently owned by institutional investors and hedge funds.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.